Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Heron Therapeutics (HRTX) Operating Margin (2016 - 2025)

Historic Operating Margin for Heron Therapeutics (HRTX) over the last 12 years, with Q3 2025 value amounting to 10.71%.

  • Heron Therapeutics' Operating Margin rose 28800.0% to 10.71% in Q3 2025 from the same period last year, while for Sep 2025 it was 1.03%, marking a year-over-year increase of 198500.0%. This contributed to the annual value of 7.99% for FY2024, which is 790800.0% up from last year.
  • Latest data reveals that Heron Therapeutics reported Operating Margin of 10.71% as of Q3 2025, which was up 28800.0% from 4.4% recorded in Q2 2025.
  • Heron Therapeutics' Operating Margin's 5-year high stood at 10.23% during Q4 2024, with a 5-year trough of 269.43% in Q2 2021.
  • Over the past 5 years, Heron Therapeutics' median Operating Margin value was 79.31% (recorded in 2023), while the average stood at 109.52%.
  • In the last 5 years, Heron Therapeutics' Operating Margin plummeted by -527200bps in 2021 and then surged by 1914100bps in 2022.
  • Over the past 5 years, Heron Therapeutics' Operating Margin (Quarter) stood at 259.2% in 2021, then surged by 74bps to 67.79% in 2022, then soared by 56bps to 29.85% in 2023, then surged by 134bps to 10.23% in 2024, then crashed by -205bps to 10.71% in 2025.
  • Its Operating Margin was 10.71% in Q3 2025, compared to 4.4% in Q2 2025 and 8.11% in Q1 2025.